General anesthesia will be used during the procedure to reduce the potential for movement during the localized ablation and to manage potential pain. Patients in the VAPOR 2 clinical study reported little to no pain. However, there can be some minor discomfort after the procedure, which typically resolves within a few days and may be managed with over-the-counter medications. Your physician will discuss pain management options as part of the preparation for the procedure.
The Vanquish® Water Vapor Ablation System has been cleared as a tool for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.